窑Original Article窑
The Third National Retrospective Sample Investigation on the Cause of Death (20042005) points out that lung cancer has become the leading cause of death in China, accounting for 22.7% of malignant tumors, with the mortality increasing by 465% in the past 30 years. At present, surgery is the standard treatment for stageII nonsmall cell lung cancer (NSCLC), but little research has been done on the prognosis of these patients since they account for a such small part of the patients treated with surgery. The benefit of postoperative adjuvant chemotherapy in patients with NSCLC is only about 4% 15% [1] . It is particularly important to identify patients with adverse factors and at high risk of recurrence, metastasis, and death, and give them individualized adjuvant therapy. Therefore, it is of great significance to study the prognostic factors in patients with stageII NSCLC. This study retrospectively analyzed the clinical data of 220 patients with completely resected stageII NSCLC at the Sun Yatsen University Cancer Center between January 1998 and December 2004, and explored the clinical factors affecting postoperative prognosis.
Between January 1998 and December 2004, 1548 NSCLC patients received surgery at the Sun Yatsen University Cancer Center , in which 220 patients with completely resected stageII NSCLC were selected. There were 176 men and 44 women, with a median age of 60 years (3082 years). According to the sixth edition of the International Union Against Cancer (UICC) Tumor Node Metastasis (TNM) classification, there were 16 patients with stageIIA (T1N1M0) disease, 204 patients with stageIIB (105 T2N1M0 and 99 T3N0M0) disease, and 96 patients with squamous cell carcinoma, 95 patients with adenocarcinoma, and 29 patients with other types (adenosquamous carcinoma, large cell carcinoma, and mucoepidermoid carcinoma). A total of 46 patients received postoperative adjuvant chemotherapy and 21 patients received adjuvant thoracic radiotherapy. All patients had no other malignant tumors. Relevant preoperative examinations were performed to exclude distant metastasis, and no patients received preoperative chemotherapy or radiotherapy.
All patients underwent complete resection, including the lung lobe (bilateral lobes) or total lung resection plus mediastinal hilar lymph node dissection, in which 154 patients received single lobe resection, 58 patients received bilateral lobe resection, and 8 patients received pneumonectomy. In addition to the lung lobes, and interlobar and hilar lymph nodes, at least the left mediastinal lymph nodes at levels 5/6 and 7 and right mediastinal lymph nodes at levels 2, 4, and 7 were dissected. The bronchial stump was required to be pathologically negative.
The observation indicators included age, sex, symptoms (the presence of symptoms, chest pain, cough), disease duration, blood type, smoking index, surgical method (whole lung, single lung lobe, bilateral lobes), TNM stage, pathologic type, degree of differentiation, tumor diameter, tumor size (pathologic specimen volume = (length × width × height)/2) 2 , the total number of lymph nodes dissected, and the total number of N2 lymph nodes dissected, the number of positive N1 lymph nodes, the degree of N1 lymph node metastasis, the lobe location of the tumor, postoperative adjuvant chemotherapy, and adjuvant radiotherapy.
The best cutoff points were selected referring to the mean values of continuous variables and their receiver operating characteristic (ROC) curves impacting the survival rate, and continuous variables were divided into 2 categories. Specific cutoff points were as follows: an age of 55 years, smoking index of 400, tumor diameter of 3 cm, tumor volume of 20 cm 3 , a total of 10 dissected lymph nodes, a total of 6 dissected N2 lymph nodes, a total of 3 positive N1 lymph nodes, and a ratio of N1 lymph node metastasis of 35%. SPSS version 16.0 was used. A 字 2 test was used for comparing count data. Survival and diseasefree survival rates were calculated by the KaplanMeier method, and a logrank test was used for univariate survival analysis. The Cox proportional hazards model was used for analyzing statistically significant factors found in the univariate analysis. A value of < 0.05 has considered statistically significant.
Up to June 1, 2008, the median followup time was 50 months (2137 months), and the 5year followup rate was 94.55% . In the 220 patients with completely resected stageII NSCLC, 127 patients died, of whom 121 died of lung cancer and 6 died of other causes. A total of 86 (39.1% ) patients had recurrence or metastasis, of whom 62 died of lung cancer, 2 died of other causes, and 22 were still alive. In the 86 patients with metastasis, 27 had simple recurrence at the ipsilateral chest and 59 had metastases outside the ipsilateral chest, including the lung (35 patients), bone (19), brain (8), liver (6), and adrenal glands (5). The 3year overall survival rate was 58.8% and the 5year survival rate was 47.9% , with an average survival time of (72.2 依 3.9) months, (95% CI, 64.51079.790), and a median overall survival time of (50.0 依 9.4) months (95% CI, 31.48268.518). The 3year diseasefree survival rate was 45.8% and the 5year diseasefree survival rate was 37.0%, with an average diseasefree survival time of (57.8 依 3.8) months (95% CI, 50.29165.241) and a median diseasefree survival time of (27.0 依 3.9) months (95% CI, 19.28634.714).
The univariate analysis showed that age, blood type, the presence of symptoms, the presence of chest pain, tumor size, the total number of dissected lymph nodes, the number of dissected N2 lymph nodes, the number of positive N1 lymph nodes, and the ratio of N1 lymph node metastasis had a relationship with prognosis ( < 0.05) (Table 1) . Sex, disease duration, the presence of cough, TNM stage (IIA and IIB), pathologic type, degree of differentiation, tumor diameter, the number of dissected N2 lymph nodes, the lobe where the tumor was located, surgical method (whole lung, single lung lobe, or bilateral lobes), postoperative adjuvant chemotherapy, and adjuvant radiotherapy had no relationship with prognosis ( > 0.05) ( Table 1 ).
The statistically significant indicators in univariate analysis were introduced into the Cox proportional hazards model (the forward stepwise method) to perform multivariate analysis. In the final model, the independent factor for a favorable prognosis was the total number of dissected lymph nodes greater than or equal to 10, and the independent factors for poor prognosis were being older than 55 years, having chest pain before surgery, having a tumor volume larger than 20 cm 3 , and having more than 3 dissected N1 positive lymph nodes (Table 2 and Figure 5 Overall survival curves of patients with the number of involved N1 lymph nodes < 3 and 逸 3
T1a (臆 2 cm) and T1b (> 2 cm and 臆 3 cm); (2) T2 was divided into T2a (> 3 cm and 臆 5 cm) and T2b (> 5 cm and 臆7 cm); (3) tumors larger than 7 cm were classified as T3 instead of the original T2; (4) separate tumor nodules in the same lobe were classified as T3 instead of the original T4; and (5) separate tumor nodules in different ipsilateral lobes were classified as T4 instead of the original M1. Changes related to stage II included T2bN0M0 being classified as IIA instead of IB and T2aN1M0 being classified as IIA instead of IIB. Tumors with a diameter greater than 7 cm were classified as T3 instead of the original T2, the original T2N0M0 IB was restaged as T3N0M0 IIB, and the original T2N1M0 IIB was restaged as T3N1M0 IIIA (Table 3 ).
The natural survival rate of patients with stageII NSCLC has been reported in few research studies. It was reported [3] that 31 patients without surgery, radiotherapy, or chemotherapy had a median survival time of 11 months and a 2year survival rate of only 6%. The 5year survival rate of patients with stageII NSCLC after surgery was 32% 50% [48] . In this study, the 5year survival Figure 4 Overall survival curves of patients with the total number of removed lymph nodes < 10 and 逸 10 rate was 47.9% , which was in line with the reported literature. TNM stage was an important prognostic indicator. In this study, the 5year survival rates of IIA (pT1N1M0) and IIB (pT2N1M0, pT3N0M0) were 61.9% and 46.8%, respectively, without statistical significance. A number of previous studies [6, 9] , have found that the difference between the survival curves of patients with stageIIA and IIB disease had no statistical significance.
According to the new edition of the TNM classification released in 2009 [10, 11] , although the proportion of patients with stageIIA disease has increased, the survival curves of IIA and IIB still cross at the fifth year, indicating that the distinction between stageIIA and IIB disease is still inadequate. In this study, restaging according to the seventh edition, patients with stageIIA disease increased from 16 patients to 88 patients, but the 5year survival rate decreased from 61.9% to 49.5% , while the patients with stageIIB disease decreased from 204 patients to 116 patients with no significant change in the 5year survival rate. This may be relevant to the change from stage IIB to stage IIA. However, the data cannot fully reflect the real status of the new stage IIB, because T2bN0M0 IIA and T3N0M0 IIB from the original IB were not included in this study, separate tumor nodules in the same lobe were classified as T3 instead of the original T4, and this kind of T3N0M0 IIB was not included too. According to the new stages, 16 patients with tumor diameters more than 7 cm, which were restaged as T3N1M0 III, were excluded. According to the seventh edition, the number and proportion of patients with stageIIA disease were more than in the sixth edition, and changes in disease stage would lead to changes in treatment. The N0 patients with tumor diameters of 57 cm and more than 7 cm had changed stages from IB to IIA and IIB, and adjuvant chemotherapy is worthy of further study in these patients. At present, most research proposes that age is a prognostic factor of NSCLC. Two large retrospective analyses (13 010 patients and 6644 patients) from Japan [5, 7] showed that the patients younger than 50 years had significantly better prognosis than those older than 70 years. Chansky . [10] reported that age was an independent prognostic factor of patients with NSCLC after surgery and patients younger than 70 years had a better prognosis than those older than 70 years. Kuo . [12] reported that in patients with NSCLC, compared with the old group (older than 80 years), women and patients with adenocarcinoma accounted for the majority of the youth group (younger than 40 years) with more treatment and better prognosis. In this study, age was an independent prognostic factor, both the 3 and 5year survival rates of patients younger than or equal to 55 years were higher than for those older than 55 years, which might be because the general condition and immune status of younger patients was better than older patients, and at the same time, these two groups had different compositions by sex, pathologic type, stage, and other indicators. Further analysis showed that in patients younger than or equal to 55 years, there were more women than in those older than 55 years, with a different sex ratio between the 2 groups (28.9% vs. 15.3%, 字 2 = 5.810, = 0.016). Although our data did not show sex as a prognosisrelated factor, many studies [57, 10, 13, 14] found that being a woman was an independent factor for favorable prognosis. Therefore, sex and age are likely to produce a common effect on prognosis.
Many studies [6, 14] have proposed that symptoms or performance status were prognostic factors. Our data showed that both symptoms and chest pain had an impact on prognosis. The 5year survival rate of asymptomatic patients (discovered by physical examination) was significantly higher than that of those with symptoms, while the 5year survival rate of patients with chest pain was significantly lower than that of those without chest pain. Further analysis found that in the chest pain group, the proportion of patients with stage T3N0M0 disease was significantly higher than in the nonchest pain group (68.1% vs. 38.7% , 字 2 = 14.556, < 0.001). No patient with chest pain was found with T1N1M0 disease, and patients with chest pain all had stageIIB disease. It could be seen that chest pain in patients with stageIIB disease was mostly associated with the violation of the parietal pleura, and these patients mostly had stageT3 disease and worse prognosis than those without chest pain.
The maximum tumor diameter is an important basis for T staging, but lung cancer mostly has irregularly shaped tumors, and diameter alone does not provide enough accuracy. Iwasaki . [15] reported in 385 patients with completely resected NSCLC, univariate analysis showed that tumor diameter and volume were both prognostic factors, while in multivariate analysis neither had significance, but the author still recommended that tumor volume should be calculated preoperatively by computed tomography to estimate prognosis. Tsai .
[2] reported a retrospective study of 236 patients with stageIA NSCLC, and found that the tumor volume of postoperative specimens could be a better representation of tumor size and was an independent prognostic factor. Our data found that tumor specimen volume was an independent prognostic factor for patients with stageII NSCLC, while tumor diameter had no significance in either univariate or multivariate analysis. Therefore, tumor specimen volume was a better prognostic indicator than tumor diameter, and the 5year survival rate of patients with tumor specimen volumes more than 20 cm was significantly lower than that of those with tumor volumes less than or equal to 20 cm 3 . In this study it was found that the total number of dissected lymph nodes more than or equal to 10 was a favorable prognostic factor, and the 5year survival rate of patients with the total number of dissected lymph nodes more than or equal to 10 was significantly higher than those with less than 10. Similar studies [1618] have similar results that the total number of dissected lymph nodes is a prognostic factor, the specific number ranging from 6 to 15. The adequate number of dissected lymph nodes may have 3 roles: (1) with more dissected lymph nodes at each level and more dissected levels, the probability of finding lymph node metastasis will increase, which leads to more accurate pathologic N stage, and downgrades and excludes patients that do not have stageI disease; (2) dissection of positive lymph nodes can play a therapeutic effect in early NSCLC; and (3) lymph node dissection can reduce local recurrence and distant metastasis and improve overall survival rates. Gajra . [16] found that patients with stageI NSCLC with more than 6 lymph nodes dissected had higher overall survival rates and lower risks of recurrence, and the number was an independent prognostic factor. Wu . [17] found that the total number of dissected lymph nodes affected overall survival in patients with stageI NSCLC and adequate lymph node dissection should remove at least 15 lymph nodes. Recently, Varlotto . [18] reported that patients with stageI NSCLC with lymph node dissection had a better prognosis than those without lymph node dissection, and at least 11 lymph nodes should be dissected.
Lymph node metastasis is one of the significant ways NSCLC metastasizes. In this study it was found that having more than 3 positive N1 lymph nodes was an independent poor prognostic factor in patients with stageII NSCLC. With the increase of tumor burden in the lymph nodes, this might indicate a risk of recurrence and an increase in metastasis. Similarly, Marra . [19] analyzed patients with stageN1 NSCLC and found in univariate analysis the number of positive N1 lymph nodes was related to the 5year overall survival rate, but in multivariate analysis it was not. Cerfolio . [13] found that in patients with stageN1 NSCLC, those with multiple N1 lymph node metastases had a worse overall survival than those with single positive N1 lymph node, and the number of positive N1 lymph nodes was an independent prognostic factor. However, recently, Gonfiotti .
[20]
did not find a relationship between the number of positive N1 lymph nodes and prognosis in patients with N1positive NSCLC.
In conclusion, in patients with completely resected stageII NSCLC, the independent factor for favorable prognosis was having at least 10 dissected lymph nodes, and the independent factors for poor prognosis were being older than 55 years, having chest pain before surgery, having tumor volumes larger than 20 cm 3 , and having more than 3 dissected positive N1 lymph nodes. Patients with adverse prognostic factors should receive stronger postoperative followup and active individualized adjuvant therapy to reduce the risk of recurrence, metastasis, and death. Although there are many prognostic factors in NSCLC, including continuously discovered new molecular indicators, a practical prediction system has not been formed. The independent predictors for patients with completely resected stageII NSCLC found in this study cannot accurately predict the prognosis of patients, but can provide a reference to further prospective clinical research on prognosis.
